← Back to Clinical Trials
Recruiting NCT07057973

The Effectiveness of Preoperative Iron Therapy in Improving Anemia After Multi-level Lumbar Fusion in the Elderly

Trial Parameters

Condition Ferric Carboxymaltose
Sponsor Xuanwu Hospital, Beijing
Study Type INTERVENTIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age 60 Years
Max Age 90 Years
Start Date 2025-07-01
Completion 2026-07-01
Interventions
Ferric carboxymaltose

Brief Summary

Preoperative iron therapy has important value in improving the outcomes after lumbar fusion surgery, but there is significant heterogeneity in both domestic and international studies. International studies provide high-level evidence-based evidence for intravenous iron, but lack spinal surgery-specific data; domestic studies focus on the comparison of iron types and the improvement of clinical practice, but high-quality evidence is still insufficient. At present, there are still few studies on preoperative iron therapy in the field of spinal surgery, especially its specific impact on the prognosis of patients after lumbar fusion surgery is still unclear. Therefore, it is particularly important to study the preoperative iron supplementation regimen for lumbar fusion surgery to improve the efficacy and safety. Through multidisciplinary collaboration and technological innovation, preoperative iron therapy is expected to become an important part of accelerated recovery after lumbar fusion surgery.

Eligibility Criteria

Inclusion Criteria: * All patients underwent multi-segment lumbar spine surgery; * IDA patients aged 65 years or older (male: Hb \< 120g/dL; female: Hb \< 110g/dL); * All patients completed the relevant questionnaire survey; Exclusion Criteria: * Age less than 65 years old; * Previous surgery for spinal tumors, trauma or infection; * Inflammatory or immune diseases (such as rheumatoid arthritis or systemic lupus erythematosus), acute kidney injury, progressive cancer and porphyria cutanea tarda); * Non-adjacent segment surgery; * History of allergy to ferric carboxymaltose or any intravenous iron preparations, asthma, atopic dermatitis or allergy; * Decompensated cirrhosis and microcytic anemia; * Incomplete clinical data;

Related Trials